BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 26518061)

  • 21. What Does the Boxed Warning Tell Us? Safe Practice of Using Ferumoxytol as an MRI Contrast Agent.
    Varallyay CG; Toth GB; Fu R; Netto JP; Firkins J; Ambady P; Neuwelt EA
    AJNR Am J Neuroradiol; 2017 Jul; 38(7):1297-1302. PubMed ID: 28495944
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Emerging applications for ferumoxytol as a contrast agent in MRI.
    Bashir MR; Bhatti L; Marin D; Nelson RC
    J Magn Reson Imaging; 2015 Apr; 41(4):884-98. PubMed ID: 24974785
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cardiovascular MRI with ferumoxytol.
    Finn JP; Nguyen KL; Han F; Zhou Z; Salusky I; Ayad I; Hu P
    Clin Radiol; 2016 Aug; 71(8):796-806. PubMed ID: 27221526
    [TBL] [Abstract][Full Text] [Related]  

  • 24. High resolution, 3-dimensional Ferumoxytol-enhanced cardiovascular magnetic resonance venography in central venous occlusion.
    Shahrouki P; Moriarty JM; Khan SN; Bista B; Kee ST; DeRubertis BG; Yoshida T; Nguyen KL; Finn JP
    J Cardiovasc Magn Reson; 2019 Mar; 21(1):17. PubMed ID: 30853026
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Safety and technique of ferumoxytol administration for MRI.
    Vasanawala SS; Nguyen KL; Hope MD; Bridges MD; Hope TA; Reeder SB; Bashir MR
    Magn Reson Med; 2016 May; 75(5):2107-11. PubMed ID: 26890830
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efficacy and tolerability of nebivolol monotherapy by baseline systolic blood pressure: a retrospective analysis of pooled data from two multicenter, 12-week, randomized, double-blind, placebo-controlled, parallel-group, dose-ranging studies in patients with mild to moderate essential hypertension.
    Germino FW
    Clin Ther; 2009 Sep; 31(9):1946-56. PubMed ID: 19843484
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Current and potential imaging applications of ferumoxytol for magnetic resonance imaging.
    Toth GB; Varallyay CG; Horvath A; Bashir MR; Choyke PL; Daldrup-Link HE; Dosa E; Finn JP; Gahramanov S; Harisinghani M; Macdougall I; Neuwelt A; Vasanawala SS; Ambady P; Barajas R; Cetas JS; Ciporen J; DeLoughery TJ; Doolittle ND; Fu R; Grinstead J; Guimaraes AR; Hamilton BE; Li X; McConnell HL; Muldoon LL; Nesbit G; Netto JP; Petterson D; Rooney WD; Schwartz D; Szidonya L; Neuwelt EA
    Kidney Int; 2017 Jul; 92(1):47-66. PubMed ID: 28434822
    [TBL] [Abstract][Full Text] [Related]  

  • 28. 4D flow image quality with blood pool contrast: a comparison of gadofosveset trisodium and ferumoxytol.
    Mukai K; Burris NS; Mahadevan VS; Foster ED; Ordovas KG; Hope MD
    Int J Cardiovasc Imaging; 2018 Feb; 34(2):273-279. PubMed ID: 28884401
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Vascular artifact mimicking thrombosis on MR imaging using ferumoxytol as a contrast agent in abdominal vascular assessment.
    Fananapazir G; Marin D; Suhocki PV; Kim CY; Bashir MR
    J Vasc Interv Radiol; 2014 Jun; 25(6):969-76. PubMed ID: 24630749
    [TBL] [Abstract][Full Text] [Related]  

  • 30. High-resolution, whole-body vascular imaging with ferumoxytol as an alternative to gadolinium agents in a pediatric chronic kidney disease cohort.
    Nayak AB; Luhar A; Hanudel M; Gales B; Hall TR; Finn JP; Salusky IB; Zaritsky J
    Pediatr Nephrol; 2015 Mar; 30(3):515-21. PubMed ID: 25212105
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Safety and effectiveness of ferumoxytol in hemodialysis patients at 3 dialysis chains in the United States over a 12-month period.
    Schiller B; Bhat P; Sharma A
    Clin Ther; 2014 Jan; 36(1):70-83. PubMed ID: 24315802
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Ferumoxytol magnetic resonance angiography: a dose-finding study in patients with chronic kidney disease.
    Stoumpos S; Hennessy M; Vesey AT; Radjenovic A; Kasthuri R; Kingsmore DB; Mark PB; Roditi G
    Eur Radiol; 2019 Jul; 29(7):3543-3552. PubMed ID: 30919067
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Retrospective assessment of the utility of an iron-based agent for contrast-enhanced magnetic resonance venography in patients with endstage renal diseases.
    Bashir MR; Mody R; Neville A; Javan R; Seaman D; Kim CY; Gupta RT; Jaffe TA
    J Magn Reson Imaging; 2014 Jul; 40(1):113-8. PubMed ID: 24130008
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Renal transplant imaging using magnetic resonance angiography with a nonnephrotoxic contrast agent.
    Bashir MR; Jaffe TA; Brennan TV; Patel UD; Ellis MJ
    Transplantation; 2013 Jul; 96(1):91-6. PubMed ID: 23680931
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Ferumoxytol: a new era of iron deficiency anemia treatment for patients with chronic kidney disease.
    Kowalczyk M; Banach M; Rysz J
    J Nephrol; 2011; 24(6):717-22. PubMed ID: 21956770
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Accuracy of the CNAP™ monitor, a noninvasive continuous blood pressure device, in providing beat-to-beat blood pressure readings in pediatric patients weighing 20-40 kilograms.
    Kako H; Corridore M; Rice J; Tobias JD
    Paediatr Anaesth; 2013 Nov; 23(11):989-93. PubMed ID: 23565770
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Ferumoxytol: a new intravenous iron preparation for the treatment of iron deficiency anemia in patients with chronic kidney disease.
    Schwenk MH
    Pharmacotherapy; 2010 Jan; 30(1):70-9. PubMed ID: 20030475
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Ferumoxytol magnetic resonance imaging detects joint and pleural infiltration of bone sarcomas in pediatric and young adult patients.
    Theruvath AJ; Rashidi A; Nyalakonda RR; Avedian RS; Steffner RJ; Spunt SL; Daldrup-Link HE
    Pediatr Radiol; 2021 Dec; 51(13):2521-2529. PubMed ID: 34410452
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A multicenter, 14-week study of telmisartan and ramipril in patients with mild-to-moderate hypertension using ambulatory blood pressure monitoring.
    Lacourcière Y; Neutel JM; Davidai G; Koval S
    Am J Hypertens; 2006 Jan; 19(1):104-12. PubMed ID: 16461201
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A twelve-week, multicenter, randomized, double-blind, parallel-group, noninferiority trial of the antihypertensive efficacy and tolerability of imidapril and candesartan in adult patients with mild to moderate essential hypertension: the Iberian Multicenter Imidapril Study on Hypertension (IMISH).
    Palma Gámiz JL; Pêgo M; Contreras EM; Anglada MP; Martínez JO; Esquerra EA; Sagastagoitia Gorostiza JD;
    Clin Ther; 2006 Dec; 28(12):2040-51. PubMed ID: 17296460
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.